Conference Track

Focus on Investigational HBV/HCV Agents

Source: CCO Official Conference Coverage of the 2008 AASLD Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

R7128 Plus Peginterferon Alfa-2a/Ribavirin Produces High RVR Rates in Previous Nonresponders Infected With Genotype 2 or 3 HCV
Nonnucleoside HCV Polymerase Inhibitor PF-00868554 Safe and Effective in Treatment-Naive Patients Infected With Genotype 1 HCV
Adding Boceprevir to Standard Peginterferon/Ribavirin Regimen Boosts SVR Rates in Treatment-Naive Patients Chronically Infected With Genotype 1 HCV
Reducing Nitazoxanide Pretreatment to 4 Weeks Does Not Compromise Antiviral Effect of Subsequent Nitazoxanide and Peginterferon alfa-2a Combination Therapy in Treatment-Naive HCV Patients
Short-term HCV Protease Inhibitor MK-7009 Monotherapy Well Tolerated and Effective in Patients With Genotype 1 HCV Infection
12-Week Telaprevir Induction With 24-Week Peginterferon alfa-2a/Ribavirin Therapy Achieves Higher SVR Rates Than 48-Week Standard of Care in Treatment-Naive Genotype 1 HCV Patients
Significantly Greater SVR Rates With Telaprevir-Based Therapy Than Standard of Care Retreatment in Previous Unsuccessfully Treated Genotype 1 HCV-Infected Patients
Weight-Based Taribavirin Demonstrates Similar Efficacy, Less Anemia vs Ribavirin When Both Combined With Peginterferon alfa-2b
Clevudine Provides Greater Viral Suppression and HBeAg Seroconversion vs Lamivudine in HBeAg-Positive Chronic Hepatitis B at 48 Weeks
Retrospective Analysis: Virologic and Biochemical Efficacy With Clevudine Comparable to Entecavir in Nucleoside-Naive Patients Through 48 Weeks
Rapid Decline in HCV RNA Followed by Viral Breakthrough With BI201335 Monotherapy in Treatment-Naive, Genotype 1 HCV-Infected Patients
Comparable Rates of HCV RNA Suppression With Telaprevir 2 or 3 Times Daily Plus Peginterferon/Ribavirin in Treatment-Naive Patients With Genotype 1 HCV Infection
R7128 With Peginterferon alfa-2a and Ribavirin Produces High RVR Rates in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection

Expert Analysis

Focus on Investigational HBV/HCV Agents

Faculty:

Nezam H. Afdhal, MD, FRCPI
Fred Poordad, MD
Stefan Zeuzem, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data on the use of protease inhibitors for the treatment of HCV infection
Recount data on novel polymerase inhibitors for the treatment of HCV infection
Describe the role of ribavirin and/or ribavirin analogues with HCV treatments in development
Describe new data on novel agents in development for the treatment of HBV infection

CME CREDIT INFORMATION

Release Date: 01/08/09

Expiration Date: 01/07/10

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.25 contact hours (0.13 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.